Armata Pharmaceuticals, Inc. (ARMP)
NYSE
Closed
Oct 8, 2026
Day's Range
3.6052 wk Range
3.09Overview - ARMP - Armata Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
420.88M
P/E (Trailing)
‪-0.73‬
P/E (Forward)
‪-1.72‬
PEG Ratio
‪0.0013‬
Price / Sales (TTM)
‪23.61‬
Price / Book
‪-0.41‬
EV / EBITDA
‪-12.58‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-410.83%‬
Return on Assets
‪-25.83%‬
Return on Equity
‪79.50%‬
Ownership
Shares Outstanding
37.18M
Float
11.90M
Short % of Shares Outstanding
‪8.56%‬
Held by Insiders
‪67.63%‬
Held by Institutions
‪13.45%‬
Price stats
Beta
‪1.34‬
50-Day Avg
‪4.73‬
200-Day Avg
‪7.32‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
2 analysts
Average price target
‪$ 17.50‬Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ARMP - Armata Pharmaceuticals, Inc.
Peers - ARMP - Armata Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NYSE.
- ARMPNYSEArmata Pharmaceuticals, Inc.130.88MMarket Cap+9.09%52-week change-0.73P/E (Trailing)‪0.00%‬Profit Margin
- BIONYSEBio-Rad Laboratories Inc.9.87BMarket Cap+16.25%52-week change44.96P/E (Trailing)‪8.58%‬Profit Margin
- BHVNNYSEBiohaven Ltd.1.94BMarket Cap-23.39%52-week change-1.88P/E (Trailing)‪0.00%‬Profit Margin
- BSTNYSEBlackRock Science and Technology Trust1.76BMarket Cap+21.83%52-week change7.02P/E (Trailing)‪0.00%‬Profit Margin
- BCXNYSEBlackRock Resources & Commodities Strategy Trust991.85MMarket Cap+22.29%52-week change4.66P/E (Trailing)‪0.00%‬Profit Margin
- ANRONYSEAlto Neuroscience Inc.973.20MMarket Cap+73.63%52-week change-11.34P/E (Trailing)‪0.00%‬Profit Margin
- ATTONYSEAttovia Therapeutics Inc.783.83MMarket Cap-27.55%52-week change-7.23P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - ARMP - Armata Pharmaceuticals, Inc.
About
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
